Genevant Sciences
http://www.genevant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genevant Sciences
Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
Moderna’s Suit Against Pfizer Could Result In ‘Modest Royalties’ Paid By Both Rivals
Moderna seeks damages for sales of Comirnaty in US and other wealthy countries from 8 March onward, a timeframe driven by Moderna's accessibility pledge. Suit claims Pfizer and BioNTech copied two key features of its mRNA technology for their rival COVID vaccine.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice